Plexxikon is a leader in the discovery and development of novel small molecule pharmaceuticals to treat human disease. Since operations commenced June 2001, Plexxikon has applied its proprietary platform technology to identify and build a portfolio of product opportunities for therapeutic indications in metabolic disorders, cardiovascular disease, inflammation and oncology.Current Plexxikon programs address disease targets that are already validated in humans, have clear clinical development paths for significant unmet markets, and demonstrate Plexxikon's capability to address side effects and/or enhance the therapeutic profile of current drug treatments.
Plexxikon's discovery process utilizes a number of technologies, including Plexxikon's Scaffold-Based Drug Discovery™ platform. This discovery platform involves structural screening and analysis as one key component providing a significant competitive advantage to other drug discovery approaches. Structural screening is applied at the earliest point in lead finding to address current challenges in pharmaceutical drug discovery today – by enabling the mining of novel chemical space, applying a unique quality filter, and by providing a roadmap for lead discovery and development chemistry.
| Contact Details: |
| 91 Bolivar Drive |
| Berkeley |
| California |
| 94710 |
| United States of America |
| Tel: | 510.647.4000 |
| Fax: | 510.548.8014 |
| Email: | info@plexxikon.com |
| WWW: | www.plexxikon.com/
|
|
Loading...
|
Recent Publications by Plexxikon Inc.: |  |
Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells.
Context: The V600E mutation accounts for the vast majority of thyroid... | 3rd November, 2009
| Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto
| J Clin Endocrinol Metab. 2009 Oct 30.
DOI Direct Link |
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.
In a search for more effective anti-diabetic treatment, we used a process... | 14th February, 2009
| Plexxikon Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA.
| Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. Epub 2008 Dec 30.
DOI Direct Link |
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
Cyclic nucleotide phosphodiesterases (PDEs) comprise a large family of... | 1st June, 2005
| Plexxikon Inc., 91 Bolivar Dr., Berkeley, California 94710, USA.
| Nat Biotechnol. 2005 Feb;23(2):201-7. Epub 2005 Jan 30.
DOI Direct Link |
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.
Phosphodiesterases (PDEs) comprise a family of enzymes that modulate the... | 4th September, 2004
| Plexxikon Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA.
| Mol Cell. 2004 Jul 23;15(2):279-86.
DOI Direct Link |
Raf pathway inhibitors in oncology.
Recognition of the importance of the Raf pathway in the proliferation and... | 23rd March, 2004
| Plexxikon Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA.
| Curr Opin Investig Drugs. 2003 Dec;4(12):1436-41.
|
→View more Plexxikon Inc. research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 592 times since April 2007, the link to the organisation's website has been followed 73 times
Recent Search Terms used to find this page: Plexxikon abstract | plexxikon | plexxikon drug side effects | plexxikon inc | plx4032 abstract title ecco | plexxikon | plexxikon | U.S. patents no. 7,498,342 | plexxikon | Plexxikon | .
Search for more companies in Berkeley
Search for more companies in California
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Plexxikon Inc.
